Article 83 of the European Patent Convention is the 'quiet clause' that can invalidate a patent for insufficient disclosure.

True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...

Explore how multi-angle light scattering enhances biosimilar analysis by delivering accurate molecular weight and size ...

Tariffs, EV costs and challenges, and fundamental architectural and technology improvements add up to transformative ...

ED boarding has become a widespread and chronic issue exacerbated by factors such as reduced inpatient capacity, staffing ...

By embracing data over pressure, Nigeria can reduce the cost of compliance, build citizen confidence, and expand the formal ...

In March 2025, Lovable introduced “Versioning V2.0,” which makes it easier for you to track and manage any changes you’ve ...

A high-performance ecommerce development company combines strategic problem-solving with disciplined engineering to deliver ...

It’s easy to take feedback devices for granted. However, the impact this seemingly minor component can have on a system’s ...

The journey toward what the SAMANSIC Coalition terms Civilization 2.0—a stable, resilient, and sovereign global order—begins ...

The start-up Function will send practically anyone to a lab for extensive medical testing, no physical required. Is that a ...

The FDA has published new guidance aimed at reducing or stopping toxicity studies of monoclonal antibody-based drugs in non-human primates (NHPs), in the latest stage of an ongoing effort to reduce ...